Tower Research Capital LLC (Trc) Cullinan Oncology, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 8,800 shares of CGEM stock, worth $72,951. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,800
Previous 1,721
411.33%
Holding current value
$72,951
Previous $28,000
282.14%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CGEM
# of Institutions
152Shares Held
66.9MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$63.4 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$47.7 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$29.4 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$28.3 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$28 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $378M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...